Smith & Nephew Orthopaedics

Business Wire | December 29, 2016

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming January 9, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Diplomat Pharmacy, Inc. (“Diplomat” or the “Company”) (NYSE: DPLO) securities between October 9, 2014 and November 2, 2016, inclusive (the “Class Period”). Diplomat investors have until January 9, 2017 to file a lead plaintiff motion....

Pharmaphorum Media Limited | March 13, 2019

Medical equipment company Smith & Nephew has agreed a $660 million deal to buy US biotech Osiris Therapeutics that expands its business into regenerative medicine. Osiris makes medical products used to treat skin, bone and cartilage damage, with the bulk of its revenues coming from Grafix and Stravix – two cryopreserved placental tissue products used respectively as a skin substitute for wound healing and a surgical wrap for soft tissue repair. UK-based S&N is paying $19 in cash pe...

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Business Wire Press Releases | January 16, 2020

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...